The distribution of stilbamidine in the livers of normal and sarcoma-bearing mice.

In experiments preliminary to the possible use of carbon-14-labeled Stilbamidine in the treatment of humans with multiple myeloma (2, 9, 26) it was found in normal mice that no abnormal concentra tion of Stilbamidine persisted in any tissue and that over 90 per cent of the injected radioactivity was excreted within a month (20). A tracer dose of C14-labeled Stilbamidine was then given to a hu man with advanced multiple myeloma, and at autopsy 3 months later it was found that 60 per cent of the activity of the administered C14was present in the liver. Because of this finding, mice bearing several types of tumors were studied; and it was found that much larger amounts of C14(up